“…Five of these are currently FDA/EMA-approved (CT-P6, SB3, PF-05280114, ABP 980, and MYL-1401O) [ 11 , 12 , 13 , 14 , 15 ]. MYL-1401O, BCD-022, and HLX02 have phase 3 studies on metastatic breast cancer exclusively, whereas SB3, ABP 980, HD201, EG12014, and TX05 have phase 3 studies in early breast cancer patients [ 16 , 17 , 18 , 19 , 20 ]. CT-P6 and PF-05280014 conducted phase 3 studies in both MBC and EBC [ 21 , 22 , 23 , 24 ].…”